Navigation Links
COPD patients experience poorer sleep quality and lower blood oxygen levels
Date:9/20/2012

Patients with chronic obstructive pulmonary disease (COPD) experience poorer sleep quality than people of a similar age without COPD, according to research published in the journal Respirology.

Researchers also found an independent relationship between how well patients with COPD slept and the oxygen levels in their arterial blood.

"Patients with COPD frequently report fatigue, sleepiness and impaired quality of life," says Professor Walter McNicholas from the Department of Respiratory and Sleep Medicine at St. Vincent's University Hospital, Dublin, Ireland.

"The study carried out by our group, which has been researching sleep and breathing for more than 25 years, showed that such patients experience poor sleep quality, which may contribute to these debilitating symptoms."

COPD is the name for a collection of lung diseases, including chronic bronchitis, emphysema and chronic obstructive airways disease. People with COPD have trouble breathing in and out because of long-term damage to their lungs, usually because of smoking. COPD is now the fourth leading cause of chronic death and ill health in the USA and is projected to rank fifth in the burden of disease worldwide.

The current study provides a secondary analysis of two previously published trials investigating the impact of long-acting bronchodilators on night-time oxygen saturation in 106 patients with established, moderate to severe COPD. Bronchodilators make breathing easier by relaxing the muscles in the lungs and widening the airways.

Poor sleep quality was measured in a number of ways, including a reduced percentage of rapid eye movements (REM), which occur during the deepest level of sleep.

The patients covered by the study had an average age of just over 66 years, 67 per cent were male and all were current or former smokers, with a smoking history of ten or more years. Strict clinical criteria were applied to the subjects, which are outlined in full in the paper.

Key findings of the study included:

  • Patients with severe COPD experienced poorer sleep quality than people without COPD of a similar age.
  • Daytime hypoxemia (low arterial blood oxygen levels) is associated with sleep efficiency, but airflow obstruction is not. Hypoxemia is thought to impact on certain neurotransmitter levels and these mechanisms can contribute to poor sleep efficiency.
  • COPD patients took longer to fall asleep than the age-matched controls after the lights had been turned off (sleep latency) and spent less of their time in bed sleeping (sleep efficiency). They also experienced greater differences in the way they slept, with more sleep at the lightest level (stage one) and less at REM (stage five, the deepest level). Slow wave sleep (stages three and four) was reasonably well preserved.

"Our study highlights poor sleep quality in patients with COPD and demonstrates an association between daytime hypoxemia and sleep efficiency," concludes Professor McNicholas.

"However, sleep quality in COPD is determined by several factors and further studies on this topic are necessary to fully evaluate the relationship. This may identify therapeutic interventions that might improve the overall quality of life in COPD patients."


'/>"/>

Contact: Amy Molnar
sciencenewsroom@wiley.com
Wiley
Source:Eurekalert

Related medicine news :

1. The cost of glaucoma care: Small group of patients accounts for large part of costs, study finds
2. Most Forehead Lift Patients Recommend Procedure: Survey
3. Cleveland Clinic study shows vitamin E may decrease cancer risk in Cowden syndrome patients
4. Considerably more patients may benefit from effective antidiabetic drug
5. Sound level around seriously ill patients like a busy road
6. Simple tool may help evaluate risk for violence among patients with mental illness
7. Study: Gingko biloba does not improve cognition in MS patients
8. Cystic fibrosis patients of low SES are less likely to be accepted for lung transplant
9. Perceived control affects complication rates in patients with acute coronary syndrome
10. Physicians suggest expert recommendations ignore vital issues for patients
11. Docs Sensitivity to Patients Feelings Tied to Good Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... FL (PRWEB) , ... February 22, 2017 , ... Gevir, ... from deer antler velvet, announced its products are coming soon to Amazon.com, the world’s ... and Shelley Thomson as a means to develop an effective natural treatment for Shelley’s ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... its certification exam and eligibility requirements effective with the April 2017 testing period. ... 1995. , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, over ... not filling a prescription because they could not afford to pay for it. ... were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and nursing ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified ... from the mouth into the bloodstream. Far outpacing the absorption speed ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... a contract to Quality Insights to help small practices in Delaware, New Jersey, ... Program, established by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Feb. 22, 2017  Allergan plc (NYSE: AGN), ... be a Gold sponsor of the Alzheimer,s Foundation ... Tour." This tour commemorates AFA,s15 years of educating ... and programs. The tour will include AFA,s free ... and displays of the AFA Quilt to Remember. ...
(Date:2/22/2017)... Oncternal Therapeutics, Inc., a clinical-stage biotechnology ... common malignancies, today announced the closing of an ... to use the proceeds to further clinical development ... preclinical development of a new ROR1-targeted antibody-drug conjugate ... anti-ROR1 monoclonal antibody being developed to treat patients ...
(Date:2/22/2017)... NEW YORK , February 22, 2017 ... half of the 50 states in the U.S. have now legalized ... Brazil , Canada , ... , Portugal , Uruguay ... steps to legalize or decriminalize cannabis in the last two years. ...
Breaking Medicine Technology: